Company
Overview
Board Members
Company History
Business
Business Overview
Business Model
Technology
Cell-free Membrane Protein Synthesis Technology
Non-canonical Amino Acid Incorporation Technology
Partnering
News
Locations
JP
Company
Overview
Board Members
Company Mistory
Bussiness
Business Overview
Business Model
Technology
Cell-free Membrane Protein Synthesis Technology
Non-canonical Amino Acid Incorporation Technology
Partnering
News
Locations
Contact Us
JP
HOME
News
News list
Annual archive
2024
2022
2021
2020
2019
2018
2024/08/01
LiberoThera Closes 720 Million JPY of Additional Funding to Accelerate the Discovery and Development of its Antibody-based Therapeutics
2024/04/03
Presentation of anti-CCR8 antibody data at the American Association for Cancer Research Annual Meeting 2024
2022/10/03
Renewed our website.
2022/07/21
LiberoThera and Biocytogen Achieve Milestone Progress in Co-Development of Fully Human GPCR Antibody Drugs
2022/06/01
Announced relocation of research laboratory.
2022/05/01
Registered Office Address has been changed.
2021/08/05
LiberoThera Secures 300 Million JPY Financing Agreement with Taiho Ventures
2021/05/14
LiberoThera Closes 535 Million JPY Financing to Develop GPCR-targeting Therapeutics
2021/02/01
LiberoThera and Biocytogen Enter into Strategic Collaboration Agreement
2020/06/26
Toru Kanke, Ph.D. has been appointed as CEO.
2019/04/01
Registered Office Address has been changed as shown below.
2019/02/04
LiberoThera opened Nihonbashi Laboratory in Chuo-ku, Tokyo.
2018/11/01
LiberoThera opened Tsurumi Office in Tsurumi-ku, Yokohama.
2018/08/31
This corporate website was opened to the public.